JL, you're the Harvard guy, and I'm just the blue collar elf with a degree from the College of Hard... uh... Knocks, but... I'm going to have to disagree with you here.
Obviously you have to take the viewpoint seriously, but you also have to consider the source. Do you really think the cardio world doesn't know that the co-author ran the EVOLVE trial and is getting paid by AZN?
The op-ed ends like this:
"In conclusion, after a parade of failed cardiovascular outcome trials of fish oils, REDUCE-IT has shown a substantial benefit with respect to major adverse cardiovascular events. More data are needed to confirm these effects and to inform an understanding of the mechanism of action, the uniqueness of the compound tested, and the potential influence of mineral oil as the comparator. However, the finding that the risks of several cardiovascular outcomes were significantly and consistently lower with icosapent ethyl than with placebo make us hopeful that the use of icosapent ethyl can substantially improve cardiovascular health in patients with statin-controlled LDL cholesterol levels who have elevated triglyceride levels"
Read it slowly. All he is saying is that the trial does present us with some unanswered questions? WHY does EPA reduce CV events, exactly? We acknowledge that that hasn't been fully parsed out. Even with full label expansion, AMRN is going to keep running trials on EPA. Hopefully LOTS of trials.
Uniqueness -- this is self-serving, will STRENGTH show Epanova does it as well... that's not an argument for not approving Vascepa, at all. You don't get to stop one approval because another drug may be coming later.
They end by acknowledging something big has happened. Their skepticism is evident, but it's stilted -- and everyone reading the article other than Steve Nissen's wife and Pyrrh can see that. They KNOW it's getting approved. They just don't want to see their drug (which will fail) get run over.
This is not stopping approval. This is not slowing approval. Sunlight is the best disinfectant. The data is out there for all to see.